Oncotelic Therapeutics, Inc.: 10-Q filed 2019-05-15

Name: Oncotelic Therapeutics, Inc.: 10-Q filed 2019-05-15
Creator: Oncotelic Therapeutics, Inc.

What Oncotelic Therapeutics, Inc. reported in its quarterly report filed 2019-05-15 (fiscal Q1 2019): 19 published measures, 40 facts as tagged in accession 0001193125-19-147291.

This filing

Form: 10-Q (quarterly report)
Filed: 2019-05-15
Fiscal period: fiscal Q1 2019
Accession: 0001193125-19-147291 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Oncotelic Therapeutics, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2019-03-31	391,000	USD
At 2018-12-31	799,000	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2019-03-31	-783,000	USD
At 2018-12-31	-362,000	USD
At 2018-03-31	-1,087,000	USD
At 2017-12-31	-477,000	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2019-03-31	200,000	USD
At 2018-12-31	629,000	USD
At 2018-03-31	233,000	USD
At 2017-12-31	1,115,000	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2019-01-01 to 2019-03-31	-633,000	USD	90
2018-01-01 to 2018-03-31	-794,000	USD	90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2019-01-01 to 2019-03-31	-429,000	USD	90
2018-01-01 to 2018-03-31	-882,000	USD	90

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2019-03-31	-295,645,000	USD
At 2018-12-31	-295,012,000	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2019-01-01 to 2019-03-31	212,000	USD	90
2018-01-01 to 2018-03-31	184,000	USD	90

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2019-01-01 to 2019-03-31	-634,000	USD	90
2018-01-01 to 2018-03-31	-795,000	USD	90

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2019-03-31	340,000	USD
At 2018-12-31	799,000	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2019-03-31	1,174,000	USD
At 2018-12-31	1,161,000	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2019-03-31	901,000	USD
At 2018-12-31	915,000	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2019-01-01 to 2019-03-31	634,000	USD	90
2018-01-01 to 2018-03-31	795,000	USD	90

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2019-01-01 to 2019-03-31	135,000	USD	90
2018-01-01 to 2018-03-31	225,000	USD	90

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2019-03-31	41,420,000	shares
At 2018-12-31	41,420,000	shares

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

Period	Value	Unit	Days
At 2019-03-31	51,000	USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

Period	Value	Unit	Days
2019-01-01 to 2019-03-31	-633,000	USD	90
2018-01-01 to 2018-03-31	-794,000	USD	90

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2019-01-01 to 2019-03-31	499,000	USD	90
2018-01-01 to 2018-03-31	570,000	USD	90

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

Period	Value	Unit	Days
2018-01-01 to 2018-03-31	2,000	USD	90

Operating lease payments

Cash paid for operating lease liabilities during the period. It differs from lease expense recognized and excludes variable payments in some presentations.

Period	Value	Unit	Days
2019-01-01 to 2019-03-31	56,000	USD	90
2019-01-01 to 2019-01-02	112,000	USD	2

Inspect the source

Entity: Oncotelic Therapeutics, Inc. / CIK 0000908259
Captured: 2026-09-20T05:05:47.535Z
SEC response SHA-256: 6c0026f9e455c874f284117994b59a028bad3a82bccf268424724837d8c3b9db

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000908259.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))